Replies to post #55844 on Biotech Values

[DewDiligence]

>OPK – the earlier [Bevasiranib] efficacy data was not competitive with Lucentis, Avastin or even early VEGF-Trap data<

Not even close, IMO. If Bevasiranib were owned by a Big Pharma, I think the program would already have been killed.